Eupraxia Pharmaceuticals Inc. announced a public offering of common shares on September 18, 2025, pricing 12,727,273 shares at US$5.50 each for expected gross proceeds of approximately US$70 million (about C$96,712,111). The offering was made concurrently in select Canadian provinces and the United States under the company’s registration statement on Form F-10, declared effective by the U.S. Securities and Exchange Commission.

Eupraxia confirmed the successful closing of the offering on September 24, 2025, including the full exercise of the underwriters’ option to purchase additional shares. In total, 14,636,363 common shares were issued, generating gross proceeds of approximately US$80.5 million (about C$111,432,000) before deducting underwriting commissions and expenses. Cantor Fitzgerald & Co. and LifeSci Capital LLC acted as joint book-running managers, with Bloom Burton Securities Inc. as co-manager.

Legal counsel for Eupraxia was provided by Blake, Cassels & Graydon LLP (Canada) and Troutman Pepper Locke LLP (U.S.), while the underwriters were represented by Stikeman Elliott LLP (Canada) and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (U.S.). Proceeds will primarily support the advancement of Eupraxia’s clinical pipeline, regulatory submissions, R&D, business development, and general corporate purposes.